MarketBeat Compares Alnylam Pharmaceuticals and TScan Therapeutics Ratings
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
MarketBeat provided analyst ratings comparing TScan Therapeutics and Alnylam Pharmaceuticals. The comparison detailed financial metrics, noting that Alnylam Pharmaceuticals has higher revenue and earnings per share than TScan Therapeutics. TScan Therapeutics was noted as having a lower price-to-earnings ratio, indicating it was more affordable than Alnylam Pharmaceuticals.
From themarketsdaily.com
Why it matters
The comparison highlights significant differences in risk and ownership structure between the two companies. Alnylam Pharmaceuticals has a low beta of 0.28, suggesting lower stock price volatility compared to TScan Therapeutics' beta of 1.15. Furthermore, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors.
From themarketsdaily.com
Who's involved
- Alnylam PharmaceuticalsBiopharmaceutical company whose valuation and financial metrics were compared to TScan Therapeutics.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Alnylam PharmaceuticalsSpeculative
Alnylam Pharmaceuticals might see changes in investment funding due to the comparison highlighting relative weaknesses versus TScan Therapeutics.
Keep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company